Clinical Trials and Research News Weekly Roundup | S2 E24 | China COVID-19 Vaccine

TrialSite News WEEKLY YOUTUBE ROUNDUP
  • 00:41 #China’s Beijing Institute of Biological Product’s COVID-19 Vaccine Reportedly Ready for Phase III? One of the leading COVID-19 vaccine candidates could be available as soon as the end of this year, reported the WeChat account of a China government-owned Assets Supervision and Administration Commission. The candidate’s development is led by a joint effort by the Beijing Institute of Biological Product (part of China National Biotech Group Co)—apparently they have completed Phase II testing and could be ready to market the finalized vaccine as early as end of 2020 or early into 2021. In what is turning into a race between a few key companies—backed by national dollars—the U.S. under Operation Warp Speed has also declared a safe and effective vaccine will be completed by January 2021.
  • 03:36 Moderna’s #mRNA-1273 Moves with Velocity into Phase II: Will the Vaccine Meet the Operation Warp Speed Deadline of January 2021? Moderna continues to move with velocity, propelling mRNA-1273 into the Phase II stage of the #vaccine development process. The Phase II study will evaluate the safety, reactogenicity, and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The company plans to enroll 600 healthy participants across two cohorts of adults ages 18-55 years (n=300) and older adults 55 years and above (n=300). Each participant will be assigned either a placebo, a 50 μg, or a 100 μg dose at both vaccinations. These participants are then followed through 12 months after the second vaccination. Given the dosage levels during the Phase I clinical trial (25 μg and 100 μg dose levels) showed neutralizing antibody titers at or above convalescent sera and were generally well tolerated, the company decided not to pursue the 250μg dose level in this Phase II study.
  • 07:50 Combined Military Hospital Pakistan Launches Ivermectin Clinical Trial Investigating Efficacy in COVID-19 Patients: Military hospitals known as the Combined Military Hospital are Pakistan Armed Forces hospitals situated in various cantonments of Pakistan. A legacy of the British Empire, these hospitals were originally established for British troops. After becoming the Indian Army Medical Corps (IAMC), they were situated in areas that became part of Pakistan and now are known as the Combined Military Hospitals, Pakistan. Today, they offer vital medical treatment, such as in-patient and out-patient medical and surgical treatment to the military and the civilian population of Pakistan: representing millions of people. Just last month, the government provider launched a clinical trial to investigate the efficacy of ivermectin in COVID-19 patients.
  • 10:24 Great Plains Health Systems Investigate Treatment Options for COVID-19 Patients: Ivermectin Study Planned: Sanford Health and Essentia Health exemplify rock solid American Midwestern-Great Plains health systems on the front lines of the COVID-19 pandemic. Both health systems have embraced investigational therapies to treat a previously unknown, novel coronavirus as clinical investigators have scrambled for proven treatments to deal with an unprecedented modern-era health crisis. From Actemra and remdesivir to stem cell therapy and even the antiparasitic drug ivermectin—embraced in South America and parts of Asia—Great Plains’ health professionals work around the clock to help patients fight off this new and at times deadly pathogen.